These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 32785929)

  • 1. Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1.
    Darabi S; Braxton DR; Eisenberg BL; Demeure MJ
    Oncology (Williston Park); 2020 Aug; 34(8):321-327. PubMed ID: 32785929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.
    Ren D; Hua Y; Yu B; Ye X; He Z; Li C; Wang J; Mo Y; Wei X; Chen Y; Zhou Y; Liao Q; Wang H; Xiang B; Zhou M; Li X; Li G; Li Y; Zeng Z; Xiong W
    Mol Cancer; 2020 Jan; 19(1):19. PubMed ID: 32000802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed death 1 (PD-1) and its ligand (PD-L1) as a new frontier in cancer Immunotherapy and challenges for the Pathologist: state of the art.
    Callea M; Pedica F; Doglioni C
    Pathologica; 2016 Jun; 108(2):48-58. PubMed ID: 28195250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
    Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
    AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.
    Lin EM; Gong J; Klempner SJ; Chao J
    World J Gastroenterol; 2018 Jul; 24(25):2686-2697. PubMed ID: 29991874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
    Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
    Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
    Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
    J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.
    Teng F; Meng X; Kong L; Yu J
    Cancer Lett; 2018 Feb; 414():166-173. PubMed ID: 29155348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy and predictive immunologic profile: the tip of the iceberg.
    Cunha Pereira T; Rodrigues-Santos P; Almeida JS; Rêgo Salgueiro F; Monteiro AR; Macedo F; Soares RF; Domingues I; Jacinto P; Sousa G
    Med Oncol; 2021 Mar; 38(5):51. PubMed ID: 33788049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.
    Zhao P; Li L; Jiang X; Li Q
    J Hematol Oncol; 2019 May; 12(1):54. PubMed ID: 31151482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy.
    Fang XN; Fu LW
    Recent Pat Anticancer Drug Discov; 2016; 11(2):141-51. PubMed ID: 26916881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
    Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
    Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy.
    Constantinidou A; Alifieris C; Trafalis DT
    Pharmacol Ther; 2019 Feb; 194():84-106. PubMed ID: 30268773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy.
    Song Y; Li Z; Xue W; Zhang M
    Immunotherapy; 2019 Apr; 11(6):515-529. PubMed ID: 30860441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts.
    Fumet JD; Truntzer C; Yarchoan M; Ghiringhelli F
    Eur J Cancer; 2020 May; 131():40-50. PubMed ID: 32278982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients.
    Nikanjam M; Arguello D; Gatalica Z; Swensen J; Barkauskas DA; Kurzrock R
    Int J Cancer; 2020 Jun; 146(11):3087-3097. PubMed ID: 31479512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.
    Shen X; Zhang L; Li J; Li Y; Wang Y; Xu ZX
    Front Immunol; 2019; 10():1337. PubMed ID: 31258527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.